Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) announced that Sean P. Bohen, M.D., Ph.D., President and CEO will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast and any accompanying presentation materials will be accessible in the Events and Presentations section of Olema's investor relations website at ir.olema.com, and a recording will be posted after the event.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
In the Jan 5 session, OLMA declined 0.71%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Inducement option grants | Neutral | +0.4% | Reported inducement stock option grants to new employees under 2022 plan. |
| Nov 21 | Conference participation | Neutral | +8.1% | Announced participation in Evercore healthcare conference with webcast access. |
| Nov 20 | Offering closing | Negative | +13.3% | Closed $19.00 per share underwritten equity offering with $218.5M gross proceeds. |
| Nov 19 | Offering pricing | Negative | -3.5% | Priced $190.0M public offering of 10,000,000 common shares at $19.00. |
| Nov 18 | Proposed offering | Negative | +136.4% | Announced proposed common stock and pre-funded warrant offering under shelf. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news includes multiple equity offerings that drew strong positive reactions on some days, indicating the stock has at times traded counter to typical dilution concerns, while neutral corporate and conference updates have also coincided with modest to strong gains.
Over the last several months, Olema’s news flow has centered on financing and investor engagement. In mid‑November 2025, the company announced a proposed offering of common stock and pre-funded warrants, followed by pricing and then closing of a public offering that raised gross proceeds of about $218.5 million. These offering headlines saw mixed but often positive price reactions. Subsequent conference participation and inducement grant updates in late November and early December 2025 also coincided with modest to strong gains. Today’s J.P. Morgan Healthcare Conference appearance fits into this pattern of ongoing investor outreach rather than a discrete clinical or financial inflection.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast of the presentation and any accompanying materials will be available in the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
